The estimated Net Worth of Terrie Curran is at least $12.8 Milion dollars as of 15 July 2024. Mr. Curran owns over 33,848 units of Phathom Pharmaceuticals Inc stock worth over $7,063,626 and over the last 8 years she sold PHAT stock worth over $2,236,038. In addition, she makes $3,459,100 as President, Chief Executive Officer oraz Director at Phathom Pharmaceuticals Inc.
Terrie has made over 23 trades of the Phathom Pharmaceuticals Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently she sold 33,848 units of PHAT stock worth $396,699 on 15 July 2024.
The largest trade she's ever made was exercising 48,508 units of Phathom Pharmaceuticals Inc stock on 1 September 2021 worth over $371,086. On average, Terrie trades about 3,151 units every 42 days since 2016. As of 15 July 2024 she still owns at least 377,734 units of Phathom Pharmaceuticals Inc stock.
You can see the complete history of Mr. Curran stock trades at the bottom of the page.
Terrie J. Curran serves as President, Chief Executive Officer, Director of the Company. errie Curran has served as a member of our board of directors since August 2019. On December 2, 2019, as part of a planned transition, Ms. Curran succeeded Mr. Socks as Chief Executive Officer. Ms. Curran previously served as the President, Global Inflammation and Immunology Franchise at Celgene Corporation and a member of its Executive Committee from April 2017 until November 2019. Ms. Curran joined Celgene in 2013 as the U.S. Commercial Head of the I&I Franchise and built the capabilities and recruited the teams that executed the successful launch of OTEZLA, before becoming Head of Worldwide Markets. Prior to joining Celgene, she served as Senior Vice President and General Manager - Global Women’s Health at Merck & Co. Before joining Merck, Ms. Curran held a number of Country General Manager positions at Schering-Plough and Pharmacia across Europe and Asia Pacific. She currently serves on the board of Myovant Sciences Ltd., a biotechnology company, and previously served on the board of H. Lundbeck A/S, a global pharmaceutical company. Ms. Curran holds a Graduate Diploma of Marketing and a Bachelor of Applied Science (B.A.S.) from the University of Technology, Sydney. Ms. Curran’s knowledge of our business and extensive biopharmaceutical industry experience contributed to our board of directors’ conclusion that she should serve as a director of our company.
As the President, Chief Executive Officer oraz Director of Phathom Pharmaceuticals Inc, the total compensation of Terrie Curran at Phathom Pharmaceuticals Inc is $3,459,100. There are no executives at Phathom Pharmaceuticals Inc getting paid more.
Terrie Curran is 51, she's been the President, Chief Executive Officer oraz Director of Phathom Pharmaceuticals Inc since 2019. There are 8 older and 6 younger executives at Phathom Pharmaceuticals Inc. The oldest executive at Phathom Pharmaceuticals Inc is Tadataka Yamada, 75, who is the Independent Chairman of the Board.
Terrie's mailing address filed with the SEC is C/O PHATHOM PHARMACEUTICALS, INC., 100 CAMPUS DRIVE, SUITE 102, FLORHAM PARK, NJ, 07932.
Over the last 5 years, insiders at Phathom Pharmaceuticals Inc have traded over $112,538,769 worth of Phathom Pharmaceuticals Inc stock and bought 2,393,679 units worth $45,337,731 . The most active insiders traders include Capital Management, L.P.Ra ..., James N Topper oraz Pharmaceutical Co Ltd Takeda. On average, Phathom Pharmaceuticals Inc executives and independent directors trade stock every 24 days with the average trade being worth of $2,226,815. The most recent stock trade was executed by Azmi Nabulsi on 15 July 2024, trading 10,901 units of PHAT stock currently worth $127,760.
phathom pharmaceuticals, inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. the company has the rights in the united states, europe, and canada to vonoprazan, a potassium-competitive acid blocker (p-cab) that blocks acid secretion in the stomach. it is also developing vonoprazan, which is in phase iii clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of helicobacter pylori infection. the company was incorporated in 2018 and is based in buffalo grove, illinois.
Phathom Pharmaceuticals Inc executives and other stock owners filed with the SEC include: